Clinical trials: Drug Administration, Inhalation
COPD
Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD
The aim of the current study is to compare the efficacy and safety of Salmeterol/Fluticasone 50/500 mcg Inhalation Powder treatment administered via Capsair twice daily and original product Seretide Diskus 500 mcg Inhalation…
- Trial name
- COPD (NCT03363503)
- Testing
- Salmeterol/Fluticasone Capsair®, Salmeterol/Fluticasone Diskus®
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Bronchial Asthma
To Study Generic Fluticasone Propionate Inhalation Aerosol for the Treatment of Bronchial Asthma
This is a randomized, assessor-blind, placebo controlled, multicenter, clinical endpoint bioequivalence study to compare the efficacy and safety of generic fluticasone propionate inhalation aerosol USP 44 mcg (Glenmark…
- Trial name
- NCT05363202
- Testing
- Fluticasone propionate Inhalation Aerosol 44 mcg, FLOVENT HFA 44 mcg
- Where
- 11 sites in India
- Volunteers
- 790 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Asthma
A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma
This is a first in human clinical study. Part 1 of the clinical study will assess the safety and tolerability, as well as the single dose pharmacokinetics (PK), of inhaled AZD4604 in healthy volunteers (Part 1a, single ascending…
- Trial name
- NCT04769869
- Testing
- AZD4604 for inhalation via DPI, AZD4604 for IV administration, AZD4604 for oral administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Bioequivalence
A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers
ioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- NCT04546256
- Testing
- Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent, ADVAIR DISKUS® 500/50
- Where
- Greece
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Bioequivalence
A Pivotal Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- NCT04466176
- Testing
- Test Product, Reference Product
- Where
- Greece
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Bioequivalence
A Bioequivalence Study Between Fluticasone and Salmeterol vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade
Bioequivalence study between two inhaler products (discus) of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- NCT04124094
- Testing
- Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals), Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK), Activated Charcoal suspension
- Where
- Greece
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.